Acetylacetone-based chemiluminescence probes for detecting quasi-stable oxidized proteins
Acetylacetone-based chemiluminescence probes effectively detect quasi-stable oxidized proteins, addressing the lack of reliable detection methods and enabling monitoring of associated diseases through in vivo imaging and biofluid analysis.
Patent Information
- Application Number
- PCT/US2026/027867
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-14
- Filing Date
- 2026-05-12
- Publication Date
- 2026-11-19
AI Technical Summary
There is a lack of reliable methods for detecting quasi-stable oxidized proteins, which are harmful but not thermally stable and can decompose into stable oxides or degraded fragments, and their relationship with oxidative stress and chronic diseases has not been extensively explored.
Development of acetylacetone-based chemiluminescence probes that can detect quasi-stable oxidized proteins in biofluids and tissues, utilizing compounds that emit light upon reaction with oxidized proteins, suitable for in vivo imaging and disease monitoring.
The probes provide sensitive and specific detection of quasi-stable oxidized proteins, enabling monitoring of conditions and diseases associated with oxidative stress, with applications in serum, plasma, cerebrospinal fluid, and urine analysis.
Smart Images

Figure US2026027867_19112026_PF_FP_ABST
Abstract
Description
Attorney Docket No. 125141.05010.MGH 2024-647ACETYLACETONE-BASED CHEMILUMINESCENCE PROBES FOR DETECTING QUASI-STABLE OXIDIZED PROTEINSCROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to U.S. Provisional Patent Application No.63 / 805.750 filed May 14, 2025, the content of which is hereby incorporated by reference in its entirety.STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
[0002] This invention was made with government support under award number 5R01AG055413-05 (agreement 2017D001752) from the National Institutes of Health -National Institute on Aging. The government has certain rights in the invention.BACKGROUND
[0003] Typically, in a biological environment, protein oxidation engages in reactive oxygen species (ROS) and reactive nitrogen species (RNS), such as superoxide, hydrogen peroxide, hydroxyl radicals, nitric oxide, and peroxynitrite, to generate oxidized proteins (here, we interchangeably call them protein oxides). For protein oxidation, the products can be classified into three major categories. The first category of product is the formation of new protein radicals, such as oxygen and nitrogen central radicals. Normally, these protein radicals are not stable and have short lifetimes. The second major products are stable oxidized end-products such as sulfonated and nitrated proteins and degraded fragments. Such stable protein oxides have been widely studied for their implications in various diseases and fundamental biological research. Stable protein oxides can be detected using a variety of techniques, such as mass spectrometry and immunoassays.
[0004] There exists a third type of protein oxides that are quasi-stable. Such protein oxides include protein peroxides, protein hydroperoxides, and chloramine-proteins, which can be harmful to biological functions. Quasi-stable protein oxides can survive for certain periods of time (minutes to days, months, dependent on the storage conditions), but it is not thermosstable and can further decompose into stable oxides or degraded fragments. Numerous reports have investigated the relationship between chronic diseases and stable protein oxides, and between ROS levels and the seventy of diseases; however, the relationship between oxidative stress and quasi-stable protein peroxides has rarely been explored, likely due to the lack ofAttorney Docket No. 125141.05010.MGH 2024-647reliable methods. Although numerous methods have been reported for detecting ROS during biological events, developing detecting methods for such quasi-stable proteins has been rarely explored.
[0005] Chemiluminescence has been widely applied to in vitro assays, such as ELISA, western blotting, and in vivo imaging in animal models. The most significant advantages of chemiluminescence include its high sensitivity and low cost.
[0006] There exists a need for probes capable of detecting quasi-stable oxidized proteins, such as chemiluminescence probes for use in biological samples and in vivo imaging.SUMMARY OF THE INVENTION
[0007] Disclosed herein are novel chemiluminescence compounds that can be used to detect oxidized proteins, including quasi-stable oxidized proteins, in biofluids (e.g., serum, plasma and cerebrospinal fluid (CSF), and urine). The compounds and compositions described herein are also suitable for in vivo imaging of oxidized proteins and can be utilized in methods of detecting and monitoring conditions, diseases, and / or disorders.
[0008] One aspect of the present disclosure provides a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, or solvate thereof,wherein— represents a single bond or a non-covalent interaction, or is absent;represents a single bond or a double bond;X1is H or BR6R7;X2is O or is absent;each of R1, R2, and R3is independently Ci-Ce alkyl;each of R4and R5is independently H, absent, or Ci-Cs alkyl; andeach of R6and R7is independently halogen; or R6and R7together with the boron Oo\xoBxatom they are attached to form ' ' .Atorney Docket No. 125141.05010.MGH 2024-647
[0009] Another aspect of the present disclosure provides a composition comprising the compound as described herein, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and a pharmaceutically acceptable carrier, diluent, or excipient.
[0010] Another aspect of the present disclosure provides a method of detecting a protein in a subject, comprising administering an effective amount of a compound to a medium comprising the protein, wherein the protein comprises an oxidized protein, an oxidantcontaining protein, or a combination thereof; and wherein the compound is a compound as described herein, or is a compound selected from the group consisting of
[0011] Another aspect of the present disclosure provides a method of detecting or monitoring a disease or disorder associated with oxidative stress in a subject, comprising administering an effective amount of a compound to the subject; wherein the compound is a compound as described herein, or is a compound selected from the group consisting ofAtorney Docket No. 125141.05010.MGH 2024-647BRIEF DESCRIPTION OF THE DRAWINGS
[0012] Some embodiments of the disclosure are described herein with reference to the accompanying figures that make apparent to a person having ordinary skill in the art how some embodiments of the disclosure may be practiced. The figures are for the purpose of illustrative discussion and no attempt is made to show structural details of an embodiment in more detail than is necessary for a fundamental understanding of the teachings of the disclosure. Where dimensions or ranges are provided in the text or figures, these are merely exemplary' and do not limit the scope or spirit of the disclosed invention.
[0013] FIG. 1 shows in vitro chemiluminescence of CRANAD-61 (50 pM) in phosphate-buffered saline (PBS) buffer with 20% THF.
[0014] FIG. 2 shows in vitro chemiluminescence of CRANAD-123 (50 pM) with H2O2 in PBS buffer with 20% THF or 20% DMSO.
[0015] FIG.3 shows in vitro chemiluminescence of CRANAD-123 and CRANAD-162 (2.5 pM) in PBS buffer with 20% DMSO.
[0016] FIG. 4 shows in vitro chemiluminescence of CRANAD-163 (50 pM) in PBS buffer with 20% THF.
[0017] FIG. 5 shows in vitro chemiluminescence of CRANAD-163, -165, -167, and -169 (50 pM) in PBS buffer and HC1O with 20% DMSO or THF.
[0018] FIG. 6 shows the proposed mechanism of chemiluminescence production from CRANAD-163.
[0019] FIG. 7 shows in vitro chemiluminescence of CRANAD-163 (50 pM) with different ROS species (100 pM) in PBS buffer with 20% THF.Atorney Docket No. 125141.05010.MGH 2024-647
[0020] FIG. 8 shows the reaction products isolated from the chemiluminescence generating reaction with NaOCl and CRANAD-163.
[0021] FIG. 9 shows the!H NMR spectra of the reaction products isolated from the chemiluminescence generating reaction with NaOCl and CRANAD-163.
[0022] FIG. 10 shows the proposed mechanism of chemiluminescence production from CRANAD-163 in the presence of NaOCl.
[0023] FIG. 11 shows in vitro chemiluminescence of CRANAD- 163 (50 pM) with different amino acids (2.5 mM) in the presence of NaOCl in PBS buffer with 20% THF.
[0024] FIG. 12 shows in vitro chemiluminescence of CRANAD-163 (50 pM) with NaOCl (2500 pM) albumin (50 pM), albumin / NaOCl (50 pM / 2500 pM) in PBS buffer with 20% THF.
[0025] FIG. 13 shows in vitro chemiluminescence of CRANAD-163 (50 pM) with albumin (50 pM), albumin / NaOCl (50 pM / 2500 pM) and purified oxidized albumin (after passing through NAP-5 column) in PBS buffer with 20% THF.
[0026] FIG. 14 shows in vitro chemiluminescence of CRANAD-163 (50 pM) with oxidized albumin (OA) and purified oxidized albumin (POA) with and without radical scavenger vitamin C (Vc).
[0027] FIG. 15 shows in vitro chemiluminescence of CRANAD-163 (50 pM) with different metal ions (400 pM) in the presence of NaOCl in PBS buffer with 20% THF.
[0028] FIG. 16 shows the proposed mechanism of chemiluminescence production from CRANAD-163 in the presence of Fe(III).
[0029] FIG. 17 shows in vitro chemiluminescence of CRANAD-163 (50 pM) with different concentrations of iron (Ill)-containing proteins as complexes in PBS buffer with 20% THF.
[0030] FIG. 18 shows serum-based chemiluminescence of CRANAD-163 (50 pM) with serum samples of Alzheimer's disease (AD) and healthy controls (HCs). The averaged signals of AD serum samples are about 20-fold higher than that from the healthy controls. The numbers (e.g., 741593) are taken from the labels on each serum sample and each number represents the serum of a single individual.
[0031] FIG. 19 shows serum-based chemiluminescence of CRANAD-163 (50 pM) with serum samples of diabetes and healthy controls (HCs). The averaged signals of diabetes serum samples are about 3 -fold higher than that from the healthy controls (HCs). The numbers (e.g., 870365) are taken from the labels on each serum sample and each number represents the serum of a single individual.
[0032] FIG. 20 shows serum-based chemiluminescence of CRANAD-163 (50 pM) with serum samples of multiple sclerosis (MS) and healthy controls (HCs). The averaged signals ofAtorney Docket No. 125141.05010.MGH 2024-647MS serum samples are about 5-fold higher than that from the healthy controls. The numbers (e.g., 224-0071) are taken from the labels on each serum sample and each number represents the serum of a single individual.
[0033] FIG. 21 shows serum-based chemiluminescence of CRANAD-163 (50 pM) with serum samples of pulmonary fibrosis and healthy controls (HCs). The averaged signals of pulmonary fibrosis serum samples are about 20-fold higher than that from the healthy controls. The numbers (e.g., 403-0512) are taken from the labels on each serum sample and each number represents the serum of a single individual.
[0034] FIG. 22 shows the ICP-MS measurement of iron concentrations in AD and HC serum samples, and chemiluminescence of CRANAD-163 with the serum samples.
[0035] FIG. 23 shows in vitro chemiluminescence of CRANAD-163 and CRANAD-164 (50 pM) in PBS buffer with 20% THF or DMSO.
[0036] FIG.24 shows in vitro chemiluminescence of CRANAD-164 (50 pM) with different ROS species (100 pM) in PBS buffer with 20% THF.
[0037] FIG.25 shows in vitro chemiluminescence of CRANAD- 164 (50 pM) with different amino acids (2.5 mM) in the presence of NaOCl in PBS buffer with 20% THF.
[0038] FIG.26 shows in vitro chemiluminescence of CRANAD-164 (50 pM) with different modified lysines (200 pM) in the presence of NaOCl in PBS buffer with 20% THF.
[0039] FIG.27 shows in vitro chemiluminescence of CRANAD-164 (50 pM) with different lysine and ploylysine (equal lysine concentration) (200 pM) in the presence of NaOCl in PBS buffer with 20% THF.
[0040] FIG. 28 shows in vitro chemiluminescence of CRANAD-164 (50 pM) with NaOCl (2500 pM) albumin (50 pM), albumin / NaOCl (50 pM / 2500 pM) in PBS buffer with 20% THF.
[0041] FIG.29 shows in vitro chemiluminescence of CRANAD-164 (50 pM) with different metal ions (400 pM) in the presence of NaOCl in PBS buffer with 20% THF.
[0042] FIG. 30 shows in vitro chemiluminescence of CRANAD-164 (50 pM) with purified oxidized albumin (POA) with and without heating at 90 °C.
[0043] FIG. 31 shows in vitro chemiluminescence of CRANAD-163 (50 pM) and CRANAD-164 (50 pM) with albumin and oxidized albumin, which were kept at -20 °C, after different days stored at -20 °C.
[0044] FIG. 32 shows serum-based chemiluminescence of CRANAD-164 (50 nM) with serum samples of Alzheimer’s disease and healthy controls (HCs). The averaged signals of AD serum samples are about 5-fold higher than that from the healthy controls. The number (e.g.,Attorney Docket No. 125141.05010.MGH 2024-647127-0740) are taken from the labels on each serum sample and each number represents the serum of a single individual.
[0045] FIG. 33 shows serum-based chemiluminescence of CRANAD-164 (50 nM) with serum samples of multiple sclerosis (MS) and healthy controls (HCs). The averaged signals of MS serum samples are about 4-fold higher than that from the healthy controls. The number (e.g., 642280) are taken from the labels on each serum sample and each number represents the serum of a single individual.
[0046] FIG. 34 shows serum-based chemiluminescence of CRANAD-164 (50 nM) with serum samples of diabetes and healthy controls (HCs). The averaged signals of diabetic serum samples are about 2-fold higher than that from the healthy controls. The numbers (e.g., 107-0717) are taken from the labels on each serum sample and each number represents the serum of a single individual.
[0047] FIG. 35 shows serum-based chemiluminescence of CRANAD-164 (50 nM) with serum samples of pulmonary fibrosis and healthy controls (HCs). The averaged signals of pulmonary fibrosis serum samples are about 20-fold higher than that from the healthy controls. The numbers (e.g.,403-0512) are taken from the labels on each serum sample and each number represents the serum of a single individual.
[0048] FIG. 36 shows in vivo imaging with CRANAD-164 in B6C57 mouse model and the time-course of chemiluminescence signal after intravenous injection of CRANAD-164.
[0049] FIG. 37 shows in vivo imaging with CRANAD-164 in B6C57 mouse model with LPS-induced inflammation and control and the time-course of chemiluminescence signals from the liver area at different days after the LPS treatment.
[0050] FIG. 38 shows in vitro chemiluminescence of CRANAD-X (X= -2, -3, -42, -54, -163) (50 pM) with oxidized albumin in PBS buffer with 20% THF.DETAILED DESCRIPTION OF THE INVENTION
[0051] Before the present materials and methods are described, it is understood that this invention is not limited to the particular methodology, protocols, materials, and reagents described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to limit the scope of the present invention which will be limited only by the appended claims.
[0052] As used herein, the singular forms “a,’’ “an,’" and "the" include plural forms unless the context clearly dictates otherwise. For example, the term “a compound” should beAttorney Docket No. 125141.05010.MGH 2024-647interpreted to mean ‘‘one or more compounds” unless the context clearly dictates otherwise. As used herein, the term “plurality” means “two or more.”
[0053] As used herein, “about”, “approximately,” “substantially,” and “significantly” will be understood by persons of ordinary skill in the art and will vary to some extent on the context in which they are used. If there are uses of the term which are not clear to persons of ordinary skill in the art given the context in which it is used, “about” and “approximately” will mean up to plus or minus 10% of the particular term and “substantially” and “significantly” will mean more than plus or minus 10% of the particular term.
[0054] As used herein, the terms “include” and “including” have the same meaning as the terms “comprise” and “comprising.” The terms “comprise” and “comprising” should be interpreted as being “open” transitional terms that permit the inclusion of additional components further to those components recited in the claims. The terms “consist” and “consisting of’ should be interpreted as being “closed” transitional terms that do not permit the inclusion of additional components other than the components recited in the claims. The term “consisting essentially of’ should be interpreted to be partially closed and allowing the inclusion only of additional components that do not fundamentally alter the nature of the claimed subject matter.
[0055] The phrase “such as” should be interpreted as “for example, including.” Moreover, the use of any and all exemplary language, including but not limited to “such as”, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed.
[0056] All language such as “up to,” “at least,” “greater than,” “less than,” and the like, include the number recited and refer to ranges which can subsequently be broken down into ranges and subranges. A range includes each individual member. Thus, for example, a group having 1-3 members refers to groups having 1, 2, or 3 members. Similarly, a group having 6 members refers to groups having 1, 2, 3, 4, 5, or 6 members, and so forth.
[0057] The modal verb “may” refers to the preferred use or selection of one or more options or choices among the several described embodiments or features contained within the same. Where no options or choices are disclosed regarding a particular embodiment or feature contained in the same, the modal verb “may” refers to an affirmative act regarding how to make or use and aspect of a described embodiment or feature contained in the same, or a definitive decision to use a specific skill regarding a described embodiment or feature contained in the same. In this latter context, the modal verb “may” has the same meaning and connotation as the auxiliary verb “can.”Attorney Docket No. 125141.05010.MGH 2024-647
[0058] Definitions
[0059] Definitions of specific functional groups and chemical terms are described in more detail below. For purposes of this disclosure, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75thEd., inside cover, and specific functional groups are generally defined as described therein. Additionally, general principles of organic chemistry, as well as specific functional moieties and reactivity, are described in Organic Chemistry, Thomas Sorrell, University Science Books, Sausalito, 1999; Smith and March, March’s Advanced Organic Chemistry, 5thEdition, John Wiley & Sons, Inc., New York, 2001; Larock, Comprehensive Organic Transformations, VCH Publishers, Inc., New York, 1989; Carruthers, Some Modem Methods of Organic Synthesis, 3rdEdition. Cambridge University Press. Cambridge, 1987; the entire contents of each of which are incorporated herein by reference. Derivatives of the compounds as described herein include structural variants that can be obtained by modifications of the synthesis of such compounds, as generally understood in the art of organic synthesis. As an example, esters and amides of a compound having a reactive group (e.g.. COOH, OH, or NH2) can be viewed as derivatives of the original compounds.
[0060] The term “non-covalent interaction” refers to reversible forces between atoms or molecules that do not involve the sharing of electrons. Non-limiting examples of non-covalent interactions include those known to a skilled artisan in the field, such as hydrogen bonding, van der Waals forces, ionic interactions, halogen bonding, dipole-dipole interactions, and n-effects.
[0061] The term “alkyl” as used herein refers to a monovalent saturated straight or branched hydrocarbon, such as a straight or branched group of 1-20, 1-12, 1-10, or 1-6 carbon atoms, referred to herein as C1-C20 alkyl (or Ci-2oalkyl), C1-C12 alkyl (or Ci- alkyl), C1-C10 alkyl (or Ci-ioalkyl), or Ci-Ce alkyl (or Ci-ealkyl), respectively.
[0062] The term “alkylene” refers to a divalent saturated straight or branched hydrocarbon group, such as a straight or branched group having 1-20, 1-12. 1-10, or 1-6 carbon atoms, referred to herein as a C1-C20 alkylene (or Ci-2oalkylene), C1-C12 alkylene (or Ci- alkylene), C1-C10 alkylene (or Ci-ioalkylene), or Ci-Cs alkylene (or Ci-salkylene), respectively. An exemplary alkylene group is -CH2CH2-.
[0063] The term “alkenyl” refers to a monovalent straight or branched hydrocarbon group having one or more double bonds. An alkenyl group having up to 20 carbon atoms is referred to as a C2-C20 alkenyl (or C2-2oalkenyl). Likewise, for example, an alkenyl having up to 6 carbon atoms is referred to as a C2-C6 alkenyl (or C2-ealkenyl).Attorney Docket No. 125141.05010.MGH 2024-647
[0064] The term “alkenylene” refers to a divalent straight or branched hydrocarbon group having one or more double bonds. An alkenylenyl group having up to 20 carbon atoms is referred to as a C2-C20 alkenylene (or C2-2oalkenylene). Likewise, for example, an alkenylene having up to 6 carbon atoms is referred to as a C2-C6 alkenylene (or C2-6alkenylene).
[0065] The term "alkoxy" as used herein means an alkyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom. Representative examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, 2-propoxy, butoxy, / e / 7-butoxy. pentyloxy, and hexyloxy.
[0066] The term “carboxy” or "carboxyl" as used herein refers to the group -COOH or its corresponding salts, e.g. -COONa, etc.
[0067] The term "aryl" is art-recognized and refers to a carbocyclic aromatic group. Representative aryl groups include phenyl, naphthyl, and the like. The term "aryl" includes polycyclic ring systems having two or more carbocyclic rings in which two or more carbons are common to two adjoining rings (the rings are "fused rings") wherein at least one of the rings is aromatic and, e.g., the other ring(s) may be cycloalkyls, cycloalkenyls, cycloalkynyls, and / or aryls.
[0068] The term “arylene” refers to a divalent carbocyclic aromatic group. Representative arylene groups include -CsLL-, -CioHe-, and the like. The term "arylene" includes polycyclic ring systems having two or more carbocyclic rings in which two or more carbons are common to two adjoining rings (the rings are "fused rings") wherein at least one of the rings is aromatic and, e g., the other ring(s) may be cycloalkyls, cycloalkenyls, cycloalkynyls, and / or aryls.
[0069] The term "phenyl" refers to a mono-substituted benzene ring and has a formula of -C6H5
[0070] The term "heteroaryl" is art-recognized and refers to a heterocyclic aromatic group. Representative heteroaryl groups include pyridinyL quinolinyL furanyl, thionyl, and the like. The term "heteroaryl" includes polycyclic ring systems having two or more heterocyclic rings in which two or more carbon or heteroatom are common to two adjoining rings (the rings are "fused rings") wherein at least one of the rings is a heterocyclic aromatic group and, e.g., the other ring(s) may be cycloalkyls, cycloalkenyls, cycloalkynyls, and / or aryls. In certain embodiments, the heteroaryl group is a 6-10 membered ring structure. The term "pyridyl" refers to a group derived from pyridine by removal of a hydrogen atom from a ring carbon atom in pyridine. The pyridyl group has a formula -C5H4N.
[0071] The term "cycloalkyd" refers to a monovalent saturated cyclic, bicyclic, or bridged cyclic (e.g., adamantyl) hydrocarbon group of 3-12, 3-8, 4-8, or 4-6 carbons, referred to herein,Attorney Docket No. 125141.05010.MGH 2024-647e.g., as "C4-8-cycloalkyl," derived from a cycloalkane. Unless specified otherwise, cycloalkyl groups are optionally substituted at one or more ring positions with, for example, alkanoyl, alkoxy, alkyl, haloalkyl, alkenyl, alkynyl, amido or carboxyamido, amidino, amino, aryl, arylalkyl, azido, carbamate, carbonate, carboxy, cyano, cycloalkyl, ester, ether, formyl, halo, haloalkyl, heteroaryl, heterocyclyl, hydroxyl, imino, ketone, nitro, phosphate, phosphonato, phosphinato, sulfate, sulfide, sulfonamide, sulfonyl or thiocarbonyl. In certain embodiments, the cycloalkyl group is not substituted, i.e., it is unsubstituted.
[0072] The term “cycloalkylene” refers to a divalent saturated cyclic, bicyclic, or bridged cyclic (e.g., adamantyl) hydrocarbon group having, for example, 3-12, 3-8, 4-8, or 4-6 carbons derived from a cycloalkane. An exemplary cycloalkylene group is -C3H4-. Unless specified otherwise, cycloalkylene groups are optionally substituted at one or more ring positions with, for example, alkanoyl, alkoxy, alkyl, haloalkyl, alkenyl, alkynyl, amido or carboxyamido, amidino, amino, aryl, arylalkyl, azido, carbamate, carbonate, carboxy, cyano, cycloalkyl, ester, ether, formyl, halo, haloalkyl, heteroaryl, heterocyclyl, hydroxyl, imino, ketone, nitro, phosphate, phosphonato. phosphinato. sulfate, sulfide, sulfonamido, sulfonyl or thiocarbonyl. In certain embodiments, the cycloalkylene group is not substituted, i.e., it is unsubstituted.
[0073] The terms "heterocycloalkyl" and "heterocyclic group" are art-recognized and refer to saturated, partially unsaturated, or aromatic 3- to 10-membered ring structures, alternatively 3-to 7-membered rings, whose ring structures include one to four heteroatoms, such as nitrogen, oxygen, and sulfur. The number of ring atoms in the heterocyclyl group can be specified using Cx-Cyor Cx-ynomenclature where x and y are integers specifying the number of ring atoms. For example, a C3-C7 (or C3-7) heterocyclyl group refers to a saturated or partially unsaturated 3- to 7-membered ring structure containing one to four heteroatoms, such as nitrogen, oxygen, and sulfur. The designation "C3-C7" or “C3-7” indicates that the heterocyclic ring contains a total of from 3 to 7 ring atoms, inclusive of any heteroatoms that occupy a ring atom position. In one embodiment, the heterocyclyl is piperidinyl.
[0074] The term "halogen" refers to halogen atoms F, Cl, Br, and I, or halogen substituents fluoro (-F). chloro (-C1), bromo (-Br), and iodo- (-1).
[0075] The term “haloalky 1” is art-recognized and refers to an alkyl group, as defined above, having halogen atoms, as defined above, replacing one or more hydrogen atoms. Representative haloalky l groups include trifluoromethyl, dibromoethyl, monochloropropyl, and the like.
[0076] The term "hydroxy" refers to a group of the form -OH.Atorney Docket No. 125141.05010.MGH 2024-647
[0077] The term 'diydroxyalkyl" refers to an alkyl means an alkyl, as defined herein, in which a hydrogen atom is replaced by -OH. Representative examples of hydroxy alkyl include, but are not limited to, those derived from Ci-6 alkyls, such as -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, and the like.
[0078] The term "nitro" refers to a group of the form -NO2.
[0079] The term "cyano" refers to a group of the form -CN.
[0080] Terms such as "alkyl," "cycloalkyl," "alkylene," "cycloalkylene," etc. may be preceded by a designation indicating the number of atoms present in the group in a particular instance (e.g., “Ci-4alkyl”, “Ci-C4alkyl”, “C3-6cycloalkyl”, “Cs-Cecycloalkyl”, “Ci-4alkylene”, “Ci-C4alkylene”). These designations are used as generally understood by those skilled in the art. For example, the representation "C" followed by a subscripted number indicates the number of carbon atoms present in the group that follows. Thus, "Csalkyl" is an alkyd group with three carbon atoms (i.e., n-propy 4, isopropyl). Where a range is given, as in "Ci-C4" or "Ci-4" the members of the group that follows may have any number of carbon atoms falling within the recited range. A "Ci-C4alkyl" or "Ci-4alkyl," for example, is an alkyd group having from 1 to 4 carbon atoms, however arranged (i.e., straight chain or branched).
[0081] If a group is described as being "substituted", a non -hydrogen substituent group is in the place of hydrogen on a carbon or nitrogen of that group. Thus, for example, a substituted alkyl is an alkyl in which at least one non-hydrogen group is in the place of a hydrogen on the alkyl. To illustrate, monofluoroalkyl is alkyl substituted with a fluoro group, and difluoroalkyl is alkyl substituted with two fluoro groups. It should be recognized that if there is more than one substitution on a substituent, each non-hydrogen group may be identical or different (unless otherwise stated). Substituent groups include, but are not limited to, halogen, =0, =S, cyano, nitro, fluoroalkyd, alkoxyfluoroalkyl, fluoroalkoxy, alkyl, alkenyl, alkynyl, haloalkyl, haloalkoxy, heteroalkyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocycle, cycloalkylalkyl, heteroarylalkyl, arylalkyl, hydroxy, hydroxyalk d, alkoxy, alkoxyalkyd, alkylene, ary doxy , phenoxy , benzyloxy , amino, alkylamino, acylamino, aminoalkyd, arylamino, sulfonylamino, sulfinylamino, sulfonyl, alkydsulfonyl, arylsulfonyl, aminosulfonyl, sulfinyl, -COOH, ketone, amide, carbamate, and acyl.
[0082] When a group is referred to as "unsubstituted" or not referred to as "substituted" or "optionally substituted", it means that the group does not have any substituents. If a group is described as being "optionally substituted", the group may be either (1) not substituted or (2) substituted. If a group is described as being optionally substituted with up to a particular number of non-hydrogen substituents, that group may be either (1) not substituted; or (2)Atorney Docket No. 125141.05010.MGH 2024-647substituted by up to that particular number of substituent groups or by up to the maximum number of substitutable positions on that group, whichever is less.
[0083] If substituents are described as being independently selected from a group, each substituent is selected independent of the other. Each substituent, therefore, may be identical to or different from the other substituent(s).
[0084] A person of ordinary skill in the art would be able to choose the substituents that fulfill the valency rules. For example, in a non-solvated or non-salt form of a compound, nitrogen typically has three bonds attached to it and oxygen typically has two bonds attached to it.
[0085] The compounds of the disclosure may contain one or more chiral centers and / or double bonds and, therefore, exist as stereoisomers, such as geometric isomers, enantiomers or diastereomers. The term “stereoisomers” when used herein consist of all geometric isomers, enantiomers or diastereomers. These compounds may be designated by the symbols “R” or “S,” depending on the configuration of substituents around the stereogenic carbon atom. The present disclosure encompasses various stereo isomers of these compounds and mixtures thereof. Stereoisomers include enantiomers and diastereomers. Mixtures of enantiomers or diastereomers may be designated "(±)" in nomenclature, but the skilled artisan will recognize that a structure may denote a chiral center implicitly. It is understood that graphical depictions of chemical structures, e.g., generic chemical structures, encompass all stereoisomeric forms of the specified compounds, unless indicated otherwise.
[0086] Site specific substitution of atoms having the same atomic number but an atomic mass or mass number different from the atomic mass or mass number that predominates in nature can be regarded as a substituent of a compound of the present disclosure. A sample of a compound having such an isotope as a substituent has at least 50% isotope incorporation at the labelled position(s). The concentration of such isotopes, e.g., deuterium, may be defined by the isotopic enrichment factor. The term “isotopic enrichment factor” as used herein means the ratio between the isotopic abundance and the natural abundance of a specified isotope. For example, if a substituent in a compound of this invention is denoted deuterium, such compound has an isotopic enrichment factor for each designated deuterium atom of at least 3500 (52.5% deuterium incorporation at each designated deuterium atom), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium incorporation), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuteriumAttorney Docket No. 125141.05010.MGH 2024-647incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation).
[0087] As used herein, '‘salt’’ refers to acid addition salts and basic addition salts. It may also refer to those salts that may be prepared in situ during the final isolation and purification of the present compounds.
[0088] The term “pharmaceutically acceptable salt thereof' means a salt prepared by combining a compound of formula (I) with an acid whose anion, or a base whose cation, is generally considered suitable for human consumption. Pharmaceutically acceptable salts are particularly useful as products of the methods of the present invention because of their greater aqueous solubility relative to the parent compound. For use in medicine, the salts of the compounds of this invention are non-toxic “pharmaceutically acceptable salts". Salts encompassed within the term “pharmaceutically acceptable salts” refer to non-toxic salts of the compounds of this invention which are generally prepared by reacting the free base with a suitable organic or inorganic acid.
[0089] Suitable pharmaceutically acceptable acid addition salts of the compounds of the present invention when possible include those derived from inorganic acids, such as hydrochloric, hydrobromic, hydrofluoric, boric, fluoroboric, phosphoric, metaphosphoric, nitric, carbonic, sulfonic, and sulfuric acids, and organic acids such as acetic, benzenesulfonic, benzoic, citric, ethanesulfonic, fumaric, gluconic, glycolic, isothionic, lactic, lactobionic, maleic, malic, methanesulfonic, trifluoromethanesulfonic, succinic, toluenesulfonic, tartaric, and tri fluoroacetic acids. Suitable organic acids generally include, for example, aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic, and sulfonic classes of organic acids. Specific examples of suitable organic acids include acetate, trifluoroacetate, formate, propionate, succinate, glycolate. gluconate, digluconate, lactate, malate, tartaric acid, citrate, ascorbate, glucuronate, maleate, fumarate, pyruvate, aspartate, glutamate, benzoate, anthranilic acid, stearate, salicylate, p-hydroxybenzoate, phenylacetate, mandelate, embonate (pamoate), methanesulfonate, ethanesulfonate, benzenesulfonate, pantothenate, toluenesulfonate, 2-hy dr oxy ethanesulfonate, sufanilate, cyclohexylaminosulfonate, P-hydroxybutyrate, galactarate, galacturonate, adipate, alginate, butyrate, camphorate, camphorsulfonate, cyclopentanepropionate, dodecylsulfate, glycoheptanoate, glycerophosphate, heptanoate, hexanoate, nicotinate, 2-naphthalesulfonate, oxalate, palmoate, pectinate, 3-phenylpropionate, picrate, pivalate, thiocyanate, and undecanoate.
[0090] Furthermore, where the compounds of the invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may include alkali metal salts, i.e., sodium orAttorney Docket No. 125141.05010.MGH 2024-647potassium salts; alkaline earth metal salts, e.g., calcium or magnesium salts; and salts formed with suitable organic ligands, e.g., quaternary ammonium salts. In another embodiment, base salts are formed from bases which form non-toxic salts, including aluminum, arginine, benzathine, choline, diethylamine, diolamine, glycine, lysine, meglumine, olamine, tromethamine and zinc salts.
[0091] Base addition salts include those derived from inorganic bases, such as ammonium or alkali or alkaline earth metal hydroxides, carbonates, bicarbonates, and the like. Bases useful in preparing such salts include sodium hydroxide, potassium hydroxide, ammonium hydroxide, potassium carbonate, sodium carbonate, sodium bicarbonate, potassium bicarbonate, calcium hydroxide, calcium carbonate, and the like.
[0092] Organic salts may be made from secondary, tertiary or quaternary amine salts, such as tromethamine, diethylamine, N, N’-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine), and procaine. Basic nitrogen-containing groups may be quatemized with agents such as lower alkyl (Ci-Ce) halides (e.g. methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides), dialkyl sulfates (i.e., dimethyl, diethyl, dibutyl, and diamyl sulfates), long chain halides (e.g., decyl, lauiyL myristyl, and stearyl chlorides, bromides, and iodides), arylalkyl halides (e.g., benzyl and phenethyl bromides), and others.
[0093] The particular counter-ion forming a part of any salt of a compound disclosed herein may not be critical to the activity of the compound, so long as the salt as a whole is pharmacologically acceptable and as long as the counter-ion does not contribute undesired qualities to the salt as a whole. Undesired qualities may include undesirably solubility or toxicity.
[0094] Pharmaceutically acceptable esters and amides of the compounds can also be employed in the compositions and methods disclosed herein. Examples of suitable esters include alkyl, aryl, and aralkyl esters, such as methyl esters, ethyl esters, propyl esters, dodecyl esters, benzyl esters, and the like. Examples of suitable amides include unsubstituted amides, monosubstituted amides, and disubstituted amides, such as methyl amide, dimethyl amide, methyl ethyl amide, and the like.
[0095] The compositions and methods disclosed herein may comprise solvate forms of the compounds or salts, esters, and / or amides, thereof. Solvate forms may include ethanol solvates, hydrates, and the like.
[0096] The compounds utilized in the compositions and methods disclosed herein may be formulated as a composition that includes a carrier. For example, the carrier may be selectedAttorney Docket No. 125141.05010.MGH 2024-647from the group consisting of proteins, carbohydrates, sugar, talc, magnesium stearate, cellulose, calcium carbonate, and starch-gelatin paste.
[0097] The compounds utilized in the compositions and methods disclosed herein may be formulated as a composition (e.g., a pharmaceutical composition) that includes one or more binding agents, filling agents, lubricating agents, suspending agents, sweeteners, flavoring agents, preservatives, buffers, wetting agents, disintegrants, and effervescent agents. Filling agents may include lactose monohydrate, lactose anhydrous, and various starches; examples of binding agents are various celluloses and cross-linked polyvinylpyrrolidone, microcrystalline cellulose, such as Avicel® PH101 and Avicel® PH102, microcrystalline cellulose, and silicified microcrystalline cellulose (ProSolv SMCC™). Suitable lubricants, including agents that act on the flowability of the powder to be compressed, may include colloidal silicon dioxide, such as Aerosil®200, talc, stearic acid, magnesium stearate, calcium stearate, and silica gel. Examples of sweeteners may include any natural or artificial sweetener, such as sucrose, xylitol, sodium saccharin, cyclamate, aspartame, and acsulfame. Examples of flavoring agents are Magnasweet® (trademark of MAFCO), bubble gum flavor, and fruit flavors, and the like. Examples of preservatives may include potassium sorbate, methylparaben, propylparaben, benzoic acid and its salts, other esters of parahydroxybenzoic acid such as butylparaben, alcohols such as ethyl or benz l alcohol, phenolic compounds such as phenol, or quaternary compounds such as benzalkonium chloride.
[0098] Suitable diluents may include pharmaceutically acceptable inert fillers, such as microcrystalline cellulose, lactose, dibasic calcium phosphate, saccharides, and mixtures of any of the foregoing. Examples of diluents include microcrystalline cellulose, such as Avicel® PH101 and Avicel® PH102; lactose such as lactose monohydrate, lactose anhydrous, and Pharmatose® DCL21; dibasic calcium phosphate such as Emcompress®; mannitol; starch; sorbitol; sucrose; and glucose.
[0099] Suitable disintegrants include lightly crosslinked polyvinyl pyrrolidone, com starch, potato starch, maize starch, and modified starches, croscarmellose sodium, cross-povidone, sodium starch glycolate, and mixtures thereof.
[0100] Examples of effervescent agents are effervescent couples such as an organic acid and a carbonate or bicarbonate. Suitable organic acids include, for example, citric, tartaric, malic, fumaric, adipic, succinic, and alginic acids and anhydrides and acid salts. Suitable carbonates and bicarbonates include, for example, sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, magnesium carbonate, sodium glycine carbonate,Attorney Docket No. 125141.05010.MGH 2024-647L-lysine carbonate, and arginine carbonate. Alternatively, only the sodium bicarbonate component of the effervescent couple may be present.
[0101] Compounds
[0102] Disclosed herein are compounds capable of generating chemiluminescence, including a series of novel acetylacetone-based scaffolds. Preliminary mechanism studies suggest that the initial step for generating chemiluminescence involves the formation of carbanion at the 3-position of acetylacetone. This mechanism is largely different from other scaffolds for generating chemiluminescence. Advantageously, the chemiluminescent compounds described herein can be used to detect quasi-stable oxidized proteins in vitro, in biofluids (e.g., serum), and can be applied to in vivo imaging.
[0103] One aspect of the present disclosure provides a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, or solvate thereof.wherein— represents a single bond or a non-covalent interaction, or is absent;= represents a single bond or a double bond;X1is H or BR6R7;X2is O or is absent;each of R1, R2, and R3is independently Ci-Ce alkyl;each of R4and R5is independently H, absent, or Ci-Ce alkyl; andeach of R6and R7is independently halogen; or R6and R7together with the boron atomwozoBthey are attached to form ' ' .
[0104] In some embodiments, the compound of Formula (I) may have a structure of Formula (I-a) or (I-b).Attorney Docket No. 125141.05010.MGH 2024-647
[0105] In some embodiments, R1and R2are identical, such as R1and R2are both ethyl. In some embodiments, R1and R2are methyl.
[0106] In some embodiments, R3is methyl. In some embodiments, R3is / -butyl.
[0107] In some embodiments, X1is H. In some embodiments, X1is BF2. In some embodiments, X1is BR6R7and R6and R7together with the boron atom they are attached toAttorney Docket No. 125141.05010.MGH 2024-647OH 0 _ X A f / w '^yzBSNx>'Q
[0109] In some embodiments, the compound of Formula (I) may beF y F
[0110] The compounds described herein can generate chemiluminescence in the presence of oxidants and are capable of detecting quasi-stable oxidized proteins in vitro or in biofluids (e.g., in serum samples), or be applied to in vivo imaging methods.
[0111] The compounds described herein are also capable of detecting ROSs, including but are not limited to H2O2, HOC1, O2‘, TBHP, NO. and NaClO.
[0112] Another aspect of the present disclosure provides a composition (e.g., a pharmaceutical composition) comprising the compound disclosed herein, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and a pharmaceutically acceptable carrier, diluent, or excipient. Conventional carriers, diluents, or excipients known in the field of chemical and pharmaceutical science may be adopted.
[0113] Methods
[0114] While numerous methods have been reported for detecting reactive oxygen species (ROS), reactive nitrogen species (RNS), and stable protein oxides in vitro and in vivo, compositions and methods for detecting secondary products of the ROS / RNS reactions, particularly quasi-stable oxidized proteins (z.e., protein oxides), have been rarely explored. Disclosed herein are chemiluminescent compounds and compositions comprising the same suitable for detecting quasi-stable protein oxides. Advantageously, the compounds and compositions disclosed herein may be used as probes for detecting or monitoring conditions, diseases and / or disorders in a subject.Atorney Docket No. 125141.05010.MGH 2024-647
[0115] As used herein, the term "disorder" refers to a condition in which there is a disturbance of normal functioning. A "disease" is any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. Sometimes the term is used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function, while in other contexts these may be considered distinguishable categories. It should be noted that the terms "disease", "disorder", "condition" and "illness", are equally used herein.
[0116] As used herein, ‘'subject” may include mammals and non-mammals. Mammals include any member of the class Mammalia. Examples of mammals include, but are not limited to, humans, non-human primates such as chimpanzees and other apes and monkey species; farm animals such as cattle, horses, sheep, goats, and swine; domestic animals such as rabbits, dogs, and cats; laboratory animals including rodents, such as rats, mice, guinea pigs, and the like. Examples of non-mammals include, but are not limited to, birds, fish, crustaceans, among others. A subj ect can be any suitable age or sex. In some embodiments, the subj ect is a human. In some embodiments, the subject is a mouse.
[0117] Another aspect of the present disclosure provides a method of detecting an ROS or a protein in a subject, comprising administering an effective amount of a compound to a medium comprising the ROS or the protein. The protein may comprise an oxidized protein, an oxidant-containing protein, or a combination thereof. In some embodiments, the compound may be a compound as described herein. In some embodiments, the compound may be selected from the group consisting ofAtorney Docket No. 125141.05010.MGH 2024-647
[0118] In some embodiments, the oxidized protein comprises a quasi-stable oxidized protein. Quasi-stable oxidized protein refers to protein oxides (used interchangeably herein with oxidized proteins) that can survive for certain periods of time (minutes to days, months, dependent on the storage conditions) but are not thermos-stable. Quasi-stable oxidized proteins can further decompose into stable oxides or degraded fragments. Therefore, quasi-stable oxidized proteins may be more reactive than the stable protein oxides and less reactive than ROSs. Non-limiting examples of quasi-stable protein oxides include protein peroxides, protein hydroperoxides, chloramine-proteins, and combinations thereof.
[0119] In some embodiments, the oxidized protein comprises oxidized albumin.
[0120] In some embodiments, the oxidant-containing protein may comprise an iron-containing protein, such as an iron(III)-containing protein. In some embodiments, the iron-containing protein comprises ferritin, hemoglobin, or hemin.
[0121] As used herein, '‘detecting an ROS” or “detecting a protein” refers to detecting the presence of the ROS or the protein, and / or determining levels of the ROS or the protein in the subject. In some embodiments, the method comprises determining levels of the protein in the subject. In some embodiments, determination of protein levels may be achieved by obtaining chemiluminescence signals and quantifying levels of the chemiluminescence signals.
[0122] In some embodiments, the compound may react with the protein, thereby generating chemiluminescence. Accordingly, the method may comprise quantifying levels of the chemiluminescence.
[0123] In some embodiments, the method may be performed in vivo. For example, in some embodiments, the medium may be the subject (e.g., a human or a mouse), and the method may comprise (i) obtaining an image of the subject, such as an image of the liver, intestine, or brain area, after administering the compound to the medium; and (ii) processing the image to obtain signals containing the levels of the chemiluminescence. For example, the image data may be quantified to determine the chemiluminescence levels.
[0124] In some embodiments, the medium may be a sample obtained from the subject, including biofluids. For example, the sample may comprise a serum sample, a plasma sample, a cerebrospinal fluid sample, or a urine sample. In some embodiments, the sample may beAtorney Docket No. 125141.05010.MGH 2024-647stored for at least 1 year, 2 years, 3 years, 4 years, 5 years, or 10 years at room temperature or at a low temperature (e g., -0°C, -5 °C. -10 °C, -15 °C, -20 °C, or -25 °C) before being subjected to the methods described herein.
[0125] In some embodiments, the method may be performed in vitro.
[0126] In some embodiments, the subject is a human. In some embodiments, the subject may have a disease or disorder associated with oxidative stress, such as a chronic disease. In some embodiments, the subject may experience oxidative stress due to aging or physical exercise.
[0127] In some embodiments, the subject may have a disease selected from the group consisting of Alzheimer's disease, diabetes, multiple sclerosis, and pulmonary fibrosis.
[0128] Another aspect of the present disclosure provides a method of detecting or monitoring a condition, disease and / or disorder associated with oxidative stress in a subject, comprising administering an effective amount of a compound to the subject. In some embodiments, the compound may be a compound as described herein. In some embodiments, the compound may be selected from the group consisting of
[0129] “Detecting a condition, disease and / or disorder” refers to identifying the presence and / or the severity of a condition, a disease and / or a disorder in a subject. “Monitoring a condition, disease and / or disorder” refers to monitoring the development or the progressionAtorney Docket No. 125141.05010.MGH 2024-647(e.g., change in severity, change in location) of a condition, a disease and / or a disorder in a subject.
[0130] In some embodiments, the method comprises determining levels of a protein in the subject. The protein may comprise an oxidized protein, an oxidant-containing protein, or a combination thereof. In some embodiments, the oxidant-containing protein may comprise an iron-containing protein, such as an iron(III)-containing protein. In some embodiments, the iron-containing protein comprises ferritin, hemoglobin, or hemin.
[0131] In some embodiments, the compound reacts with the protein, thereby generating chemiluminescence. Accordingly, the method may comprise quantifying levels of the chemiluminescence.
[0132] In some embodiments, the disease may be a chronic disease. For example, in some embodiments, the disease may be a disease selected from the group consisting of Alzheimer’s disease, diabetes, multiple sclerosis, and pulmonary fibrosis. In some embodiments, the condition associated with oxidative stress may be aging.
[0133] In some embodiments, the oxidized protein comprises a quasi-stable oxidized protein.
[0134] As used herein, the term “effective amount” refers to an amount effective, at dosages and for periods of time necessary', to achieve a desired result, including a desired result for protein detection, condition / disease / disorder detection, or condition / disease / disorder monitoring. An effective amount of the compounds as disclosed herein may vary according to factors such as the disease state and location, and age, sex, and weight of the subject, and the ability7of the disclosed compounds to elicit a desired response in the subject. Dosage regimens may be adjusted to provide the optimum response.
[0135] An effective amount can be readily determined by one skilled in the art. by the use of known techniques and by observing results obtained under analogous circumstances. In determining the effective amount or dose of compound administered, a number of factors can be considered by the attending diagnostician, such as: the species of the subject; its weight, size, age, and general health; the degree of involvement or the severity of the disease or condition involved; the response of the individual subject; the particular compound administered; the mode of administration; the bioavailability characteristics of the preparation administered; the dose regimen selected; the use of concomitant medication; and other relevant circumstances.
[0136] In some embodiments, the disclosed methods may comprise administering about 25 pM to about 1 mM, about 50 pM to about 1 mM, about 100 pM to about 1 mM, about 200 pMAttorney Docket No. 125141.05010.MGH 2024-647to about 1 mM, about 200 pM to about 900 pM, about 300 pM to about 800 pM, about 400 pM to about 700 pM, or about 500 pM of the compound per even’ 1 mg of the protein (e.g., the quasi-stable oxidized protein).
[0137] In some embodiments, the disclosed methods may detect the protein (e.g., the quasi-stable oxidized protein) with a concentration in the picomolar range or even lower ranges, such as equal to or lower than 1 nM, equal to or lower than 500 picomolar, equal to or lower than 400 picomolar, equal to or lower than 300 picomolar, equal to or lower than 200 picomolar, equal to or lower than 100 picomolar, equal to or lower than 50 picomolar, equal to or lower than 40 picomolar, equal to or lower than 30 picomolar, equal to or lower than 20 picomolar, or equal to or lower than 10 picomolar. Concentration ranges are also contemplated herein, such as concentration ranges bounded by end-point concentrations selected from 1 nM, 500 picomolar, 400 picomolar, 300 picomolar, 200 picomolar, 100 picomolar, 50 picomolar, 40 picomolar, 30 picomolar, 20 picomolar, and 10 picomolar.
[0138] In some embodiments, the chemiluminescence signals may remain detectable for at least 1 hour, 2 hours. 3 hours, 4 hours. 5 hours, 6 hours. 7 hours, 8 hours. 9 hours, or 10 hours after being generated. In some embodiments, detection of a protein, or detection and / or monitoring of a disease or disorder may be achieved at least 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, or 10 hours after administration of the compound.
[0139] The term “administering” or “administration” refers to introducing the present compounds or compositions into the medium or the body of the subject. Suitable routes of administration include, but are not limited to, oral, topical, transdermal, buccal, sublingual, pulmonary, transdermal, transmucosal, rectal, as well as subcutaneous, intraperitoneal, intravenous, and intramuscular injection. In some embodiments, the compound or composition is administered intravenously.
[0140] The compounds utilized in the methods disclosed herein may be administered in conventional forms prepared by combining the active ingredient with standard pharmaceutical carriers or diluents and, optionally, one or more additional adjuvants or ingredients according to known procedures, including for example mixing, granulating, compressing, and / or dissolving various ingredients as appropriate to the desired preparation. Standard pharmaceutical formulation techniques may be employed, such as those described in Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA.
[0141] Compounds or compositions disclosed herein may be adapted for administration by any appropriate route. Such formulations may be prepared by any method known in the art ofAtorney Docket No. 125141.05010.MGH 2024-647pharmacy, for example by bringing into association the active ingredient with the carrier(s) or excipient(s).
[0142] Intravenous administration is an illustrative route of administering the compounds employed in the compositions and methods disclosed herein. Other illustrative routes of administration include oral, transdermal, percutaneous, intramuscular, intranasal, buccal, intrathecal, intracerebral, or intrarectal routes. The route of administration may be varied in any way, limited by the physical properties of the compounds being employed and the convenience of the subject and the caregiver.
[0143] Compositions adapted for parenteral administration include aqueous and nonaqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets.
[0144] Compositions adapted for oral administration may be presented as discrete units such as capsules or tablets; powders or granules; solutions or suspensions in aqueous or non-aqueous liquids: edible foams or whips; or oil-in-water liquid emulsions or water-in-oil liquid emulsions.
[0145] Compositions adapted for transdermal administration may be presented as discrete patches intended to remain in intimate contact with the epidermis of the recipient for a prolonged period of time. For example, the active ingredient may be delivered from the patch by iontophoresis.
[0146] Compositions adapted for rectal administration may be presented as suppositories or enemas.
[0147] Tablets and capsules for oral administration may be in unit dose presentation form, and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fdlers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tableting lubricants, for example magnesium stearate, talc, polyethylene glycol or silica; disintegrants, for example potato starch; or acceptable wetting agents such as sodium lauryl sulphate. The tablets may be coated according to methods well known in normal pharmaceutical practice. Oral liquid preparations may be inAttorney Docket No. 125141.05010.MGH 2024-647the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives, such as suspending agents, for example sorbitol, methyl cellulose, glucose syrup, gelatin, hydroxyethyl cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and, if desired, conventional flavoring or coloring agents.
[0148] Regardless of composition or formulation, those skilled in the art will recognize various avenues for administration, together with corresponding factors and parameters to be considered in rendering such a medicament suitable for administration.
[0149] As one skilled in the art will appreciate, suitable formulations include those that are suitable for more than one route of administration. For example, the formulation can be one that is suitable for both oral and intravenous administration. Alternatively, suitable formulations include those that are suitable for only one route of administration as well as those that are suitable for one or more routes of administration, but not suitable for one or more other routes of administration. For example, the formulation can be one that is suitable for oral, transdermal, percutaneous, intravenous, intramuscular, intranasal, buccal, and / or intrathecal administration but not suitable for intracerebral administration.
[0150] Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary7skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described. All publications and patents specifically mentioned herein are incorporated by reference for all purposes including describing and disclosing the chemicals, cell lines, vectors, animals, instruments, statistical analysis and methodologies which are reported in the publications which might be used in connection with the invention. All references cited in this specification are to be taken as indicative of the level of skill in the art. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.EXAMPLESAttorney Docket No. 125141.05010.MGH 2024-647
[0151] The following examples are shown to further illustrate the disclosed invention and are not intended to limit the disclosed invention, as recited in the claims.
[0152] Example 1
[0153] Although numerous methods have been reported for detecting ROS during biological events, detecting methods for quasi-stable proteins have been rarely explored. In this work, it was first unexpectedly discovered that acetylacetone (beta-diketone) scaffold is a new category of chemiluminescence probes. Later, it was surprisingly found that such probes could be used for in vitro detection of quasi-stable protein oxides, likely including protein peroxides and chloramine-proteins, in patients’ serum and for in vivo imaging in animal models.
[0154] Results
[0155] 1, Discovery of acetylacetone scaffold for chemiluminescence probes. Previous near-infrared fluorescence imaging studies suggested that CRANAD-61, an oxalate ester of acetylacetone derivative (also a curcumin analogue), could react with various ROS and could be used to detect ROS in Alzheimer’s disease (AD) models. Since oxalate ester is one of the most typical scaffolds for generating chemiluminescence and the major component for glowstick production, it was speculated that CRANAD-61 should be chemiluminescent in the presence of H2O2. Indeed, chemiluminescence was observed, but the signals were extremely weak (FIG. 1). It was reasoned that the weak signal was due to the rotatable double bonds in long conjugation. To improve the efficiency, CRANAD-123 was first designed by shortening the conjugation system. As expected. CRANAD-123 showed much stronger chemiluminescence (FIG. 2). To further enhance the chemiluminescence emitting efficiency, CRANAD-162 was designed via locking-up the double-bond rotation in CRANAD-123 with a furan ring fused to the phenyl ring. Indeed, 4.5 -fold higher chemiluminescence from CRANAD-162 was observed, compared to CRANAD-123 (FIG.3). However, CRANAD-162 was not stable and could decompose to CRANAD-163, an acetylacetone derivative. Surprisingly, it was observed that CRANAD-163 was chemiluminescent in DMSO and THF solutions (FIG. 4).
[0156] For the generation of chemiluminescence from CRANAD-163, it was speculated that trace amounts of peroxide in DMSO or THF, the co-solvent used in the tests, could induce the oxidative reaction. It is known that DMSO solvent may have trace amounts of peroxides. Similarly, it is commonly known that aged THF solvents could have trace amounts of peroxides, such as tetrahydrofuran hydroperoxide. To understand the chemiluminescence generating reaction, it was speculated that the C-3 position was the key to chemiluminescence production. To further confirm this speculation, the C-3 position was blocked with partial andAttorney Docket No. 125141.05010.MGH 2024-647full blocking by one methyl and two methyl groups (CRANAD-165 and CRANAD-169). It was found that one methyl (partial blocking) could lead to a significant reduction of chemiluminescence intensity, and full blocking with two methyl groups led to a totally disappeared chemiluminescence (FIG. 5). Considering that the alpha-methyl group could also be deprotonated, the effect of blocking the deprotonation was investigated. In this regard, CRANAD-167 was synthesized using a / -butyl group to replace the methyl group. It was found that the chemiluminescence intensity was decreased but was not totally abolished (FIG. 5), suggesting that the alpha-methyl group is not crucial but has certain effects on chemiluminescence production. Here it seems that the bulky / -butyl group can reduce the intensity via hindrance interference.
[0157] Based on the above results, a tentative reaction mechanism is posited (FIG. 6). In this mechanism, the first step is deprotonation at the C-3 to provide a carbanion, which is electron-rich and can transfer an electron to an oxidant, such as peroxides, in the environment. After the single electron transfer (SET), a C-3 radical is formed. It is well known that many¬ radicals, particularly carbon radicals, can react with O2 to form peroxide radicals. In this case, the C-3 radical could also react with O2to afford a peroxide radical intermediate. The C-3-O-O’ accepts one electron from another C-3 carbanion to form a superoxide (C-3-O-O ), which further attacks the nearby carbonyl group to form dioxetane. the high energy intermediate (HEI) that emits light in the course of decomposition.
[0158] 2, Reaction of CRANAD-163 with ROS. Since observations suggested that CRANAD-162 and CRANAD-163 could react with peroxides in THF and DMSO, it was speculated that they could also react with other ROS species. In this regard, CRANAD-163 was tested with different ROS species, including H2O2, HOC1, O2‘, TBHP, and NO. Interestingly, only HOC1 showed a significant intensity increase, while apparent changes with other species were not observed (FIG. 7). To further investigate the reaction with HOC1, the reaction of CRANAD-163 with aqueous NaClO was investigated. When 1 equivalent NaClO was added to the solution of CRANAD-163. three new products were isolated, and the corresponding yields were determined by crude 'H NMR using 1,3,5-trimethoxybenzene as the internal standard. The quantitative NMR yield showed that 45% of starting material remained. The carbon-carbon bond cleavage resulted in CRANAD-163-diCl with an 8% yield and CRANAD-163-COOH with a 20% yield. A monochloride-substituted CRANAD-163-C1 was separated in a 16% yield (FIG. 8 and FIG. 9). Based on the structures of products, a mechanism involving the generation of chloronium intermediate was proposed. However,Attorney Docket No. 125141.05010.MGH 2024-647the DFT calculated ring-opening energy of the chloronium intermediate was not matched with the energy of the emitted chemiluminescence, thus it was believed that this reaction pathway was a non-chemiluminescence process. The observed chemiluminescence and the generation of carboxylate CRANAD-163-COOH indicate there is a chemiluminescence-generating pathway in which dioxetane is formed. This pathway is also supported by DFT calculations (FIG. 10)
[0159] 3, Reaction of CRANAD-163 with amino acids in the presence of NaOCl. Given that the goal is to utilize CRANAD-163 as a sensor for biological samples and an in vivo imaging probe, it was set out to investigate whether CRANAD-163 can respond to oxidized (peroxides) of individual amino acids. Given that HOC1 is well known for its strong capacity of oxidation, including oxidation of amino acids, HOC1 was used to generate oxidized amino acids and it was investigated which amino acids were responsive to CRANAD-163. To this end, the probe was tested with different amino acids in the presence of HOC1 (1.0 eq.) and it was found that tryptophan provided the highest increase in intensity (FIG. 11), suggesting that tryptophan is likely the responding amino acid. This is consistent with reports that tryptophan can form peroxide in the presence of oxidants. In this course, tryptophan reacts with1C>2, which can be generated from HOC1 decomposition, to form tryptophan hydroperoxides.
[0160] 4, Albumin as a model protein to study the chemiluminescence of CRANAD-163.To investigate whether CRANAD-163 can be responsive to quasi-stable oxidized proteins (hydroperoxides and peroxides), albumin was used as the model protein. First, it was tested whether chemiluminescence would be generated from the mixture of CRANAD-163 and albumin itself, and there was no apparent emission. To mimic a biologically relevant environment. NaOCl was used to oxidize albumin and then CRANAD-163 was used to detect the peroxides generated from the NaOCl reaction. Indeed, there was a 36-fold intensity increase for the mixture of NaOCl and albumin, compared to albumin only group, and a 7-fold increase compared to the NaOCl-only group (FIG. 12). To rule out that the increase in intensity is due to NaOCl, a NAP-5 column was used to remove the excess amount of NaOCl. Interestingly, after the column purification, the responsive time course changed. With the mixture, there was a quick response phase, while this quick phase was gone after purification (FIG. 13). The quick phase is ascribed to the reaction between HOC1 and CRANAD-163, while the slow response phase to the reaction between albumin peroxides and CRANAD-163. Likely, the reaction is due to the tryptophan hydroperoxide and CRANAD-163.Attorney Docket No. 125141.05010.MGH 2024-647
[0161] To test whether the light emission from the purified oxidized albumin originated from peroxides, several known peroxide scavengers were used. Indeed, after the addition of scavengers, the chemiluminescence disappeared (FIG. 14).
[0162] 5, CRANAD-163 and metal ions. Since numerous metal ions could be used as oxidants, CRANAD-163 was tested with a serial of metal ions. Surprisingly, strong chemiluminescence with Fe1(FIG. 15) was observed. This discovery is remarkable because acetylacetone was well known to coordinate with Fe3+, but there are no precedent reports about chemiluminescence that can be generated from the Fe3+complex. Based on the literature and the results, the following mechanism was proposed to interpret the generation of chemiluminescence (FIG. 16). First, CRANAD-163 undergoes deprotonation and then coordinates with feme ion (Fe3+). The central carbon of 1,3-diketone is oxidized to radical, which is captured by O? to generate peroxide radical. Simultaneously, the ferric ion is reduced to ferrous ion (Fe2+). The peroxide radical will integrate ferrous ion, then ferrite bond inserts into carbonyl group to form dioxetane intermediate, which decomposes to carboxylate and emits light.
[0163] Interestingly, it was also found that CRANAD-163 could produce chemiluminescence in the presence of iron-containing proteins such as ferritin and hemoglobin (FIG. 17). Similarly, hemin also could promote the generation of chemiluminescence from CRANAD-163 (FIG. 17).
[0164] 6, Patient serum tests with CRANAD-163. It is well-known that chronic diseases are highly associated with oxidative stress. It is widely believed that oxidative stress is closely related to ROS levels in vivo. However, it is not clear whether oxidative stress can be quantified, and whether serum biomarkers can be used to report the level of oxidative stress.
[0165] For serum samples, it is less likely that the samples contain highly reactive radicals and HOC1. Still, it is highly possible that sera contain quasi-stable peroxides, such as tryptophan-OOH. Given that CRANAD-163 can react with peroxides from solutions of DMSO and THF, and from oxidized albumin, it was speculated that CRANAD-163 could be used to detect the quasi-stable peroxides in patient serum samples. Tests were first performed with AD serum samples and compared to samples from healthy controls. Indeed, quite a large difference between the groups was observed. The average difference was about 13-fold higher signals from the AD group (n=12) (FIG. 18), while the largest individual AD serum showed up to 20-fold higher signal, suggesting that this method is highly sensitive. The chemiluminescence signals from the HC group were quite weak, probably suggesting that the HC samples contain minimal quasi-stable peroxides. By contrast, the chemiluminescence signals were strong fromAttorney Docket No. 125141.05010.MGH 2024-647the AD sera, and the signal could last for about 5 hours, and the maxima intensity could be observed around 15 minutes after the addition of CRANAD-163.
[0166] Notably, the serum samples have been stored in the biobanks for many years, and the highly reactive protein radicals and HOC1 should not be presented in such samples. However, CRANAD-163 could provide quite strong chemiluminescence signals from the AD group, suggesting that the method disclosed herein is capable of reporting the levels of quasistable oxidized species in serum samples.
[0167] To investigate whether similar strong chemiluminescence can be observed from sera of other chronic diseases, similar experiments were performed with sera of diabetes (n=3) (FIG. 19), multiple sclerosis (n=8) (FIG.20), and pulmonary fibrosis (FIG. 21). As expected, all the disease sera provided significantly higher chemiluminescence signals, suggesting that CRANAD-163 can be used to report the concentrations of quasi-stable peroxides.
[0168] Although the in vitro pure solution tests showed that CRANAD-163 could produce chemiluminescence in the presence of iron-containing proteins and hemin, no correlation was found between the chemiluminescence intensity’ and iron concentrations in the patient serum samples (FIG. 22), suggesting that the ion levels in serum samples have no significant contributions for the chemiluminescence differences between healthy controls and chronic disease subjects.
[0169] 7, In vivo imaging with CRANAD-163. It is highly desirable if CRANAD-163 can be used for in vivo imaging. To test out whether this is feasible, CRANAD-163 was injected into 5xFAD mice and the brain area and liver and intestine areas were imaged. Unfortunately, meaningful images via chemiluminescence imaging were not captured. Tumor models were also tested, and no apparent chemiluminescence signals could be captured. The likely reason is that CRANAD-163's chemiluminescence was not strong enough for in vivo imaging.
[0170] 8, Design of CRANAD-164 and in vitro tests and in vivo imaging. To overcome the low' chemiluminescence efficiency (brightness) of CRANAD-163, CRANAD-164 was designed by blocking the beta-di-ketone moiety with BF2coordination to limit the bond rotation and increase the molecule's rigidity. Moreover, with this modification, the formation of carbanion at the C-3 position is much easier, and this is due to the electron- withdrawing feature of BF2. Theoretically, CRANAD-164 is capable of generating chemiluminescence as CRANAD-163. Indeed, with this modification, the chemiluminescence intensity' increased 1.3-folds in THF and 116-fold in DMSO solutions (FIG. 23), compared to CRANAD-163. This also suggested that CRANAD-164 was able to detect peroxides in DMSO solutions.Atorney Docket No. 125141.05010.MGH 2024-647
[0171] Similar to CRANAD-163, CRANAD-164 was highly sensitive to NaOCl (FIG.24).It was also investigated whether CRANAD-164 could respond to oxidized (peroxides) of individual amino acids, and it was found that basic amino acids, including lysine, proline and arginine, showed the highest chemiluminescence intensity in the presence of NaOCl (FIG.25).
[0172] Although protein peroxides (hydroperoxides) could be the possible responders in the reaction of albumin and NaOCl, the responders could also be protein-chloramine because NaOCl can rapidly react with amino acids and proteins, and one of the possible products is the quasi-stable protein-chloramine. Based on the literature, NaOCl could react with lysine to produce chloramine. In this regard, lysine and NaOCl were used to check whether significant chemiluminescence signals can be observed under pH 7.4. Apparent signals were detected from the mixture. To identify which amino group of lysine is responsible for the chemiluminescence signal, cr-N-Acetylated lysine, s-N-acetylated lysine, and (ct, s)-N,N’-diacefylated lysine were tested, and it was found that the s-amino group was important for chemiluminescence, while alpha-amino has less influence (FIG. 26). If both a. s-amino groups were acetylated, the chemiluminescence nearly totally abolished (FIG. 26). The above results suggested that lysine-chloramine is the likely responder in the reaction of light emission. Polylysine was further used to perform a similar experiment and there was no significant differences in chemiluminescence intensity between lysine and polylysine (with an equal equivalent of lysine) (FIG. 27). These results suggested that chloramine was likely to be one of the responders in the oxidized albumin.
[0173] It was also found that CRANAD-164 was highly sensitive to oxidized albumin, and the increase of chemiluminescence intensity was 760-fold, compared to the native albumin (FIG. 28). Like CRANAD-163, CRANAD-164 robustly responded to Fe3+and iron (III)-containing proteins and complex (FIG. 29).
[0174] To further confirm that the signals originate from peroxides, the sera was heated to 90 °C for 5 minutes and tested with CRANAD-164. Like the case with oxidized albumin, the chemiluminescence signals were completely abolished after heating (FIG. 30). Again, this result indicated that CRANAD-164 was capable of detecting quasi-stable peroxides in serum samples, even if the samples had been stored in low temperatures for many years.
[0175] Interestingly, CRANAD-164 was also used to longitudinally monitor the peroxides of albumin. Surprisingly, strong chemiluminescence signals were observed with the purified oxidized albumin for 5 days if it was kept in -20 °C (FIG. 31). During the 5 days, the signals didn’t show apparent decreases, suggesting the protein oxides are considerably stable underAtorney Docket No. 125141.05010.MGH 2024-647such a condition. Oppositely, if the oxidized albumin was heated to 90 °C for 5 min, and then subjected to test, the chemiluminescence signals totally disappeared, suggesting that CRANAD-164 is responsive to quasi-stable peroxides of albumin. In addition, the long survival time of the oxidized albumin strongly suggested that the responders were not radicals, instead, quasi-stable peroxides could be one of the responders.
[0176] CRANAD-164 was also able to detect peroxides in serum samples of different diseases. The detected differences are similar to the results from CRANAD-163 (FIGS. 32-35).
[0177] To investigate whether CRANAD-164 is capable of in vivo imaging, an inflammation model induced by LPS with C57B6 mice was used. Two groups of mice were used for imaging. One was the control group without LPS injection and was monitored with CRANAD-164 daily. Another group was i.p. injected with LPS, and monitored daily for 7 days. Interestingly, it was observed that, before LPS treatment, the mice showed apparent chemiluminescence signals from livers. This is likely due to the highly active metabolic activity in livers. The liver signals were decayed quickly, and the signals were not detectable 40 minutes post-injection of CRANAD-164 (FIG. 36).
[0178] To investigate the changes after the LPS treatment, the imaging data were quantified and it found that the signals were significantly increased in the LPS-group, and the signals lasted at least for 4 days. While there was no apparent increase in signal from the non-LPS group (FIG. 37). Taken together, the results suggested that CRANAD-164 could be used for in vivo imaging to study the accumulation of protein oxides.
[0179] 9, Curcumin and CRANAD-X chemiluminescence. Structurally, curcumin is an acetylacetone (beta-di-keone) compound. In this regard, it was speculated that curcumin could generate chemiluminescence in the presence of an oxidant, such as HOC1. Indeed, strong chemiluminescence was observed from curcumin when HOC1 was used. Similarly, CRANAD-2, -3, -42 and -54 were able to produce chemiluminescence in the presence of HOC1 and oxidized albumin (FIG. 38). Interestingly, the long-conjugated CRANAD-Xs produced weaker chemiluminescence. This is probably due to the rotation of bonds in the long conjugation system. Taken together, the results strongly suggested that beta-diketone is the core scaffold for generating chemiluminescence.
[0180] Discussion
[0181] Numerous imaging probes and methods have been reported to detect highly reactive ROS species in vivo, and in vitro,- however, little is known about quasi-stable oxidized proteins (QSOP). This is likely due to the lack of suitable methods to detect them. In this work, it wasAtorney Docket No. 125141.05010.MGH 2024-647shown that CRANAD-163 could be used to detect such QSOPs in serum and CRANAD-164 not only for serum but also in vivo imaging.
[0182] For protein peroxides in serum, the most quasi-stable species include protein peroxides and hydroperoxides, and protein-chloramine. Although protein-chloramine has been widely studied in vitro in pure solutions, there are scarce reports about protein-chloramines in serum. Although protein-chloramines could exist in solutions for several hours, whether they can survive in serum for months and years is still an open question. The results may suggest the existence of protein-chloramines in serum.
[0183] Surprisingly, the method described herein showed that the concentrations of the QSOPs in AD were around 15-fold higher than that in healthy controls. Given such QSOPs can circulate in the blood for a considerably long time, the high levels of QSOPs may play important roles in AD pathogenesis. Data also strongly suggest that QSOPs are important AD biomarkers.
[0184] Although it was believed that CRANAD-163 and -164 detect quasi-stable protein oxides in serum, it is unclear what are the exact species capable of reacting with the probes. The most studied quasi-stable protein oxides are peroxides and hydroperoxides; however, protein-chloramines have been rarely investigated in serum and in blood. It is also well known that chloramines are widely used as disinfection agents. Again, what are the exact levels and roles in the blood system have been rarely reported.
[0185] It is very likely that the existence of quasi-stable protein oxides is a common phenomenon for chronic diseases, such as diabetes, multiple sclerosis, and pulmonary fibrosis etc. Indeed, the data disclosed herein showed that both CRANAD-163 and CRANAD-164 could provide considerable large differences in serum samples between healthy controls and these chronic diseases. However, it is a surprise that rheumatoid arthritis showed a different time course and smaller margins. Interestingly, it has been reported that Taurine-chloramine is potentially protective against rheumatoid arthritis. However, it is unclear whether protein-chloramines in the blood are protective against rheumatoid arthritis.
[0186] It is very likely that the concentrations of QSOPs are in the picomolar or even lower ranges. In the case of CRANAD-164, 50 nM was used for detection, and the detectable signals could last for 2 hours. For chemiluminescence, as is known, each probe molecule can only emit one photon because the emitting process is non-reversible. Assuming that 1) each QSOP molecule can react with CRANAD-164 with a 10% quantum yield, 2) the camera system is capable of quantitating single-photon signals (the IVIS system has a highly-sensitive CCD camera system cooled to -95°C), and 3) total 3 x 108photons / well can be collected, and thenAttorney Docket No. 125141.05010.MGH 2024-647the concentrations of QSOPs in the serum samples can be roughly calculated. By this calculation, the concentrations are in the picomolar range (~ 50 picomolar). Although the above calculation is a very rough estimation, it could be considered as one piece of evidence for the low concentrations of QSOPs in sera. On the other hand, it is explained why other methods have limited capacities to detect such low concentrations, because most of the available methods, including mass spectrometry, fluorescence, etc., are only reliable for detection in the nanomolar or higher range. However, their capacities are very limited for the picomolar range, particularly for quasi-stable materials.
[0187] If the estimation is assumed to be meaningful, this could raise an interesting point, i.e. even though the concentrations of quasi-stable protein oxides are relatively low, compared to the protein concentrations themselves, it seems that these mal-functionalized proteins circulated in blood could cause non-neglectable damage to health, evidenced by the much higher presence of QSOPs in nearly all chronic diseases, compared to healthy controls.
[0188] Although this work mainly discussed protein oxides, the oxides also could be other peroxides, such as lipid peroxides. However, lipid peroxides themselves may not be stable. Instead, numerous reports have used end-products such as MDA to reflect the level of lipid peroxide in blood. Although it has been reported that electrochemiluminescence could be observed with acetylacetone-Ir(III) complex, the chemiluminescence generation originates from the Ir(III) metal ion itself. Beta-diketone has been reported to generate chemiluminescence, but it relies on HRP and other conditions.
[0189] Interestingly, curcumin itself also produces chemiluminescence with NaOCl, and in the presence of iron (III). It is unclear whether the reaction of curcumin w ith protein oxides in serum could be used to partially explain the benefits of curcumin for AD and other diseases. Data showed that other CRANAD-X, fluorescent curcumin analogues, could be chemiluminescent as well, suggesting this is a common phenomenon for beta-diketone compounds.
[0190] In this work, several possible mechanisms were proposed to explain chemiluminescence production The data disclosed herein suggested that two pathways exist during the reaction between CRANAD-164 and NaOCl. One pathway leads to the generation of chemiluminescence, while another one decomposes CRANAD-164 without chemiluminescence production.
[0191] In this work, it was demonstrated that CRANAD-163 and CRANAD-164 could be used to report the levels of quasi-stable protein oxides in serum, and considerable large margins between diseased and healthy samples were observed. Conceivably, these probes haveAttorney Docket No. 125141.05010.MGH 2024-647the potential to monitor the generation of quasi-stable protein oxides during aging and reflect the changes in such protein oxides after physical exercise. In addition, the probes may be used to report the healthy status of blood and to reflect the status of oxidative stress. In this work, the chemiluminescence signals were used to detect protein oxides. From this point of view, it is possible to modify these probes into PET tracers for in vivo detecting protein oxides in the future.
[0192] It will be appreciated by those skilled in the art that while the disclosed subj ect matter is described above in connection with particular embodiments and examples, the invention is not necessarily so limited, and that numerous other embodiments, examples, uses, modifications and departures from the embodiments, examples and uses are intended to be encompassed by the claims attached hereto. Each reference cited herein is incorporated by reference in its entirety.
[0193] For reasons of completeness, various aspects of the invention are set out in the following numbered clauses:
[0194] Clause 1. A compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, or solvate thereof,wherein— represents a single bond or a non-covalent interaction, or is absent;= represents a single bond or a double bond;X1is H or BR6R7;X2is O or is absent;each of R1, R2, and R3is independently Ci-Ce alkyl;each of R4and R5is independently H, absent, or Ci-Cs alkyl; andeach of R6and R7is independently halogen; or R6and R7together with the boronO oBxatom they are attached to form ' 'Attorney Docket No. 125141.05010.MGH 2024-647
[0195] Clause 2. The compound of clause 1 comprising a structure of Formula (I-a) or (I-b), or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
[0196] Clause 3. The compound of clause 2, wherein R1and R2are ethyl.
[0197] Clause 4: The compound of clause 2 or clause 3, wherein R3is methyl.
[0198] Clause 5: The compound of any one of clauses 2-4, wherein X1is H.
[0199] Clause 6: The compound of any one of clauses 2-4. wherein X1is BF2.
[0200] Clause 7: The compound of clause 1, or a pharmaceutically acceptable salt, hydrate. or solvate thereof, wherein the compound isAttorney Docket No. 125141.05010.MGH 2024-647
[0201] Clause 8: The compound of clause 1, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein the compound is
[0202] Clause 9: A composition comprising the compound of any one of clauses 1-8, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and a pharmaceutically acceptable carrier, diluent, or excipient.
[0203] Clause 10: A method of detecting a protein in a subject, comprising administering an effective amount of a compound to a medium comprising the protein, wherein the protein comprises an oxidized protein, an oxidant-containing protein, or a combination thereof; and wherein the compound is the compound of any one of clauses 1-8, or is a compound selected from the group consisting ofCRANAD-42 CRANAD-54Attorney Docket No. 125141.05010.MGH 2024-647
[0204] Clause 11 : The method of clause 10, wherein the oxidized protein comprises a quasistable oxidized protein.
[0205] Clause 12: The method of clause 11, wherein the quasi-stable oxidized protein comprises protein peroxides, protein hydroperoxides, protein-chloramine, or combinations thereof.
[0206] Clause 13: The method of clause 10, wherein the oxidant-containing protein comprises an iron-containing protein.
[0207] Clause 14: The method of any one of clauses 10-13, wherein the method comprises determining levels of the protein in the subj ect.
[0208] Clause 15: The method of any one of clauses 10-14, wherein the compound reacts with the protein, thereby generating chemiluminescence; and wherein the method comprises quantifying levels of the chemiluminescence.
[0209] Clause 16: The method of clause 15, wherein the method is performed in vivo.
[0210] Clause 17: The method of clause 16, wherein the medium is the subject, and wherein the method comprises(i) obtaining an image of the subject; and(ii) processing the image to obtain signals containing the levels of the chemiluminescence.
[0211] Clause 18: The method of clause 15, wherein the medium is a sample obtained from the subject, and wherein the sample comprises a serum sample, a plasma sample, a cerebrospinal fluid sample, or a urine sample.
[0212] Clause 19: The method of clause 15, wherein the method is performed in vitro.
[0213] Clause 20: The method of any one of clauses 10-19, wherein the subject is a human.
[0214] Clause 21: The method of clause 20, wherein the subject has a disease or disorder associated with oxidative stress.
[0215] Clause 22: The method of clause 21, wherein the subject has a chronic disease.
[0216] Clause 23: The method of clause 21 or 22, wherein the subject has a disease selected from the group consisting of Alzheimer’s disease, diabetes, multiple sclerosis, and pulmonary fibrosis.Attorney Docket No. 125141.05010.MGH 2024-647
[0217] Clause 24: The method of any one of clauses 10-23, comprising administering about 100 pM to about 1 mM of the compound per every 1 mg of the protein.
[0218] Clause 25 : A method of detecting or monitoring a disease or disorder associated with oxidative stress in a subject, comprising administering an effective amount of a compound to the subject; wherein the compound is the compound of any one of clauses 1-8, or is a compound selected from the group consisting of
[0219] Clause 26: The method of clause 25, comprising determining levels of a protein in the subject, wherein the protein comprises an oxidized protein, an oxidant-containing protein, or a combination thereof.
[0220] Clause 27: The method of clause 26, wherein the compound reacts with the protein, thereby generating chemiluminescence; and wherein the method comprises quantifying levels of the chemiluminescence.
[0221] Clause 28: The method of any one of clauses 25-27, wherein the disease is a chronic disease.
[0222] Clause 29: The method of any one of clauses 25-28, wherein the disease is a disease selected from the group consisting of Alzheimer’s disease, diabetes, multiple sclerosis, and pulmonary fibrosis.
[0223] Clause 30: The method of any one of clauses 26-29, wherein the oxidized protein comprises a quasi-stable oxidized protein.Attorney Docket No. 125141.05010.MGH 2024-647
[0224] Clause 31 : The method of any one of clauses 26-30, comprising administering about 100 pM to about 1 mM of the compound per every 1 mg of the protein.
[0225] Clause 32: The method of any one of clauses 10-31, wherein the compound is administered intravenously.
Claims
Atorney Docket No. 125141.05010.MGH 2024-647CLAIMSWhat is claimed is:
1. A compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, or solvate thereof,xlR-wherein— represents a single bond or a non-covalent interaction, or is absent;= represents a single bond or a double bond;X1is H or BR6R7;X2is O or is absent;each of R1, R2, and R3is independently Ci-Ce alkyl;each of R4and R5is independently H, absent, or Ci-Cs alkyl; andeach of R6and R7is independently halogen; or R6and R7together with the boronatom they are attached to form '' '' .
2. The compound of claim 1 comprising a structure of Formula (La) or (Lb), or a pharmaceutically acceptable salt, hydrate, or solvate thereof.o 'o(La)Attorney Docket No. 125141.05010.MGH 2024-6473. The compound of claim 2, wherein R1and R2are ethyl.
4. The compound of claim 2 or claim 3, wherein R3is methyl.
5. The compound of any one of claims 2-4. wherein X1is BF2.
6. The compound of any one of claims 2-4, wherein X1is H.
7. The compound of claim 1, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein the compound isF FAttorney Docket No. 125141.05010.MGH 2024-6478. The compound of claim 1, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein the compound is9. A composition comprising the compound of any one of claims 1-8, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and a pharmaceutically acceptable carrier, diluent, or excipient.
10. A method of detecting a protein in a subject, comprising administering an effective amount of a compound to a medium comprising the protein, wherein the protein comprises an oxidized protein, an oxidant-containing protein, or a combination thereof; and wherein the compound is the compound of any one of claims 1-8, or is a compound selected from the group consisting ofCurcuminAtorney Docket No. 125141.05010.MGH 2024-64711. The method of claim 10, wherein the oxidized protein comprises a quasi-stable oxidized protein.
12. The method of claim 11, wherein the quasi-stable oxidized protein comprises protein peroxides, protein hydroperoxides, protein-chloramine, or combinations thereof.
13. The method of claim 10, wherein the oxidant-containing protein comprises an iron-containing protein.
14. The method of any one of claims 10-13, wherein the method comprises determining levels of the protein in the subject.
15. The method of any one of claims 10-14, wherein the compound reacts with the protein, thereby generating chemiluminescence; and wherein the method comprises quantifying levels of the chemiluminescence.
16. The method of claim 15, wherein the method is performed in vivo.
17. The method of claim 1 , wherein the medium is the subject, and wherein the method comprises(i) obtaining an image of the subject; and(ii) processing the image to obtain signals containing the levels of the chemiluminescence.Attorney Docket No. 125141.05010.MGH 2024-64718. The method of claim 15, wherein the medium is a sample obtained from the subject, and wherein the sample comprises a serum sample, a plasma sample, a cerebrospinal fluid sample, or a urine sample.
19. The method of claims 15, wherein the method is performed in vitro.
20. The method of any one of claims 10-19, wherein the subject is a human.
21. The method of claim 20, wherein the subject has a disease or disorder associated with oxidative stress.
22. The method of claim 21, wherein the subject has a chronic disease.
23. The method of claim 21 or 22, wherein the subject has a disease selected from the group consisting of Alzheimer’s disease, diabetes, multiple sclerosis, and pulmonary fibrosis.
24. The method of any one of claims 10-23, comprising administering about 100 pM to about 1 mM of the compound per every71 mg of the protein.
25. A method of detecting or monitoring a disease or disorder associated with oxidative stress in a subject, comprising administering an effective amount of a compound to the subject; wherein the compound is the compound of any one of claims 1-8, or is a compound selected from the group consisting of, andAttorney Docket No. 125141.05010.MGH 2024-64726. The method of claim 25, comprising determining levels of a protein in the subject, wherein the protein comprises an oxidized protein, an oxidant-containing protein, or a combination thereof.
27. The method of claim 26, wherein the compound reacts with the protein, thereby generating chemiluminescence; and wherein the method comprises quantifying levels of the chemiluminescence.
28. The method of any one of claims 25-27, wherein the disease is a chronic disease.
29. The method of any one of claims 25-28, wherein the disease is a disease selected from the group consisting of Alzheimer’s disease, diabetes, multiple sclerosis, and pulmonary fibrosis.
30. The method of any one of claims 26-29. wherein the oxidized protein comprises a quasi-stable oxidized protein.
31. The method of any one of claims 26-30, comprising administering about 100 pM to about 1 mM of the compound per every 1 mg of the protein.
32. The method of any one of claims 10-31, wherein the compound is administered intravenously.
